Immune-checkpoint inhibitors targeting PD-1 or PD-L1 have already substantially improved
the outcomes of patients with many types of cancer, although only 20–40% of patients derive …

Although precision medicine has had a mixed impact on the clinical management of patients
with advanced-stage cancer overall, for NSCLC, and more specifically for lung …

Accumulating evidence suggests that a high tumour burden has a negative effect on
anticancer immunity. The concept of tumour burden, simply defined as the total amount of …

Cancer growth and progression are associated with immune suppression. Cancer cells
have the ability to activate different immune checkpoint pathways that harbor …

Single-cell technologies have contributed to unravelling tumour heterogeneity, now
considered a hallmark of cancer and one of the main causes of tumour resistance to cancer …

The analysis of tumor cells or tumor cell products obtained from blood or other body fluids
(“liquid biopsy”[LB]) provides a broad range of opportunities in the field of oncology. Clinical …

Predictive biomarkers aid selection of personalized therapy targeted to molecular alterations
within an individual's tumor. Patients' responses to targeted therapies are commonly …

Liquid biopsy provides the opportunity of detecting, analyzing and monitoring cancer in
various body effluents such as blood or urine instead of a fragment of cancer tissue. It is …

The analysis of circulating tumor cells (CTCs) is an outstanding tool to provide insights into
the biology of metastatic cancers, to monitor disease progression and with potential for use …

The minimally—or non-invasive detection of circulating tumor-derived components in
biofluids, such as blood, liquid biopsy is a revolutionary approach with significant potential …